Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
$7.41
-$0.14(-1.13%)
At close: 4:00 PM EST
$7.41
-$0.14(-1.13%)
Day’s Range― - ―
52-Week Range$5.64 - $16.76
Previous CloseN/A
Volume175.11K
Average Volume (3M)1.28M
Market Cap
$759.02M
Enterprise Value$219.85M
Total Cash (Recent Filing)$453.10M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 10, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding102,431,930
10 Day Avg. Volume1,206,526
30 Day Avg. Volume1,276,440
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.36
Price to Sales (P/S)9.04
P/FCF Ratio-14.78
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue1.17
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$24.00Price Target Upside223.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Product AdoptionPhysicians are inclined to use Ojemda as a first-line treatment because of its once-weekly dosing in an outpatient setting, which is preferable compared to chemotherapy.
Revenue GrowthOjemda is behaving less like a traditional oncology launch and more like a rare-disease therapy: uptake is concentrated within 50–100 pediatric neuro-oncology centers of excellence, persistence on therapy is high, and revenue is compounding quarter over quarter.
Bears Say
Market ChallengesGrowth stunting is primarily the main hindrance for market adoption of Ojemda.
Share Price LimitationDAWN is strictly range bound between $6-$8/share primarily due to a lack of inflection drivers.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $16.76 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $759.02M.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 20 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.067.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.29.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 102,431,930 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went down -15.698%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
Day One Biopharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (223.89% Upside)
$24.00 (223.89% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.63%
12-Months-Change
Fundamentals
Return on Equity
-24.75%
Trailing 12-Months
Asset Growth
29.62%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Company Deck
DAWN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive sentiment with significant achievements in revenue growth, prescription numbers, and financial stability. The momentum of OJEMDA's launch and the promising pipeline developments outweighed the single noted lowlight of discontinuing the VRK1 program.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$24.00
▲(223.89% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
4.19% Insiders
20.93% Mutual Funds
28.81% Other Institutional Investors
34.50% Public Companies and
Individual Investors